NCT03759678 - N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

March 1, 2025

Study Completion Date

July 1, 2025

Conditions

Ataxia TelangiectasiaLouis Bar Syndrome

Interventions

DRUG

IB1001

IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.

Trial Locations (5)

University of California - Los Angeles, Los Angeles

University of Giessen, Giessen

Ludwig Maximilian University of Munich, München

Hospital Universitario La Paz, Madrid

Royal Papworth Hospital NHS Foundation Trust, Cambridge